FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791756039> ?p ?o ?g. }

• W2791756039 endingPage "542" @default.
• W2791756039 startingPage "532" @default.
• W2791756039 abstract "Abstract Hepatocyte growth factor (HGF)/c‐Met pathway dysregulation is a mechanism for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Ficlatuzumab (AV‐299; SCH 900105), a humanized IgG 1 κ HGF inhibitory monoclonal antibody, prevents HGF/c‐Met pathway ligand–mediated activation. This phase 1b study assessed the safety/tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of ficlatuzumab plus gefitinib in Asian patients with previously treated advanced non–small cell lung cancer (NSCLC). Patients received intravenous ficlatuzumab either 10 mg/kg (cohort 1; n = 3) or 20 mg/kg (cohort 2; n = 12) every 2 weeks plus oral gefitinib 250 mg daily. Patients tolerated the drug combination well. Four treatment‐related grade 3/4 adverse events were reported in 3 patients (cohort 2). Pharmacokinetic profiles for ficlatuzumab and gefitinib were consistent with prior single‐agent trials. Partial responses were achieved in 5 patients (4 confirmed), all in cohort 2; objective response rate (ORR) was 33% (duration, 1.9–6.4 months). Responding patients had no prior EGFR TKI treatment, 2 without an EGFR mutation. Four additional patients had disease stabilization (cohort 2; duration, 2.7–9.1 months; 42% ORR). The recommended phase 2 dose for ficlatuzumab plus gefitinib 250 mg/day was 20 mg/kg every 2 weeks. This drug combination has shown preliminary dose‐related antitumor activity in advanced NSCLC." @default.
• W2791756039 created "2018-03-29" @default.
• W2791756039 creator A5000343593 @default.
• W2791756039 creator A5003028294 @default.
• W2791756039 creator A5024674636 @default.
• W2791756039 creator A5026328342 @default.
• W2791756039 creator A5030107272 @default.
• W2791756039 creator A5030926405 @default.
• W2791756039 creator A5034739279 @default.
• W2791756039 creator A5035273217 @default.
• W2791756039 creator A5037905104 @default.
• W2791756039 creator A5048208940 @default.
• W2791756039 creator A5057964704 @default.
• W2791756039 creator A5059269204 @default.
• W2791756039 creator A5073819873 @default.
• W2791756039 creator A5082025437 @default.
• W2791756039 creator A5086361192 @default.
• W2791756039 date "2018-01-18" @default.
• W2791756039 modified "2023-10-16" @default.
• W2791756039 title "Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC" @default.
• W2791756039 cites W1619850371 @default.
• W2791756039 cites W1963497189 @default.
• W2791756039 cites W1963677580 @default.
• W2791756039 cites W1970060533 @default.
• W2791756039 cites W1985264867 @default.
• W2791756039 cites W1989635250 @default.
• W2791756039 cites W1993996642 @default.
• W2791756039 cites W2002937040 @default.
• W2791756039 cites W2003984225 @default.
• W2791756039 cites W2014230197 @default.
• W2791756039 cites W2019607817 @default.
• W2791756039 cites W2043696829 @default.
• W2791756039 cites W2055191970 @default.
• W2791756039 cites W2059250591 @default.
• W2791756039 cites W2061704066 @default.
• W2791756039 cites W2072120492 @default.
• W2791756039 cites W2074242691 @default.
• W2791756039 cites W2095673635 @default.
• W2791756039 cites W2095950160 @default.
• W2791756039 cites W2101329867 @default.
• W2791756039 cites W2113045327 @default.
• W2791756039 cites W2115269346 @default.
• W2791756039 cites W2117199959 @default.
• W2791756039 cites W2119351872 @default.
• W2791756039 cites W2120859657 @default.
• W2791756039 cites W2123061084 @default.
• W2791756039 cites W2136390065 @default.
• W2791756039 cites W2140334822 @default.
• W2791756039 cites W2142850084 @default.
• W2791756039 cites W2166084034 @default.
• W2791756039 cites W2167344440 @default.
• W2791756039 cites W2168554121 @default.
• W2791756039 cites W2501877819 @default.
• W2791756039 cites W2508077438 @default.
• W2791756039 doi "https://doi.org/10.1002/cpdd.427" @default.
• W2791756039 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6032914" @default.
• W2791756039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29346833" @default.
• W2791756039 hasPublicationYear "2018" @default.
• W2791756039 type Work @default.
• W2791756039 sameAs 2791756039 @default.
• W2791756039 citedByCount "17" @default.
• W2791756039 countsByYear W27917560392018 @default.
• W2791756039 countsByYear W27917560392019 @default.
• W2791756039 countsByYear W27917560392020 @default.
• W2791756039 countsByYear W27917560392021 @default.
• W2791756039 countsByYear W27917560392022 @default.
• W2791756039 countsByYear W27917560392023 @default.
• W2791756039 crossrefType "journal-article" @default.
• W2791756039 hasAuthorship W2791756039A5000343593 @default.
• W2791756039 hasAuthorship W2791756039A5003028294 @default.
• W2791756039 hasAuthorship W2791756039A5024674636 @default.
• W2791756039 hasAuthorship W2791756039A5026328342 @default.
• W2791756039 hasAuthorship W2791756039A5030107272 @default.
• W2791756039 hasAuthorship W2791756039A5030926405 @default.
• W2791756039 hasAuthorship W2791756039A5034739279 @default.
• W2791756039 hasAuthorship W2791756039A5035273217 @default.
• W2791756039 hasAuthorship W2791756039A5037905104 @default.
• W2791756039 hasAuthorship W2791756039A5048208940 @default.
• W2791756039 hasAuthorship W2791756039A5057964704 @default.
• W2791756039 hasAuthorship W2791756039A5059269204 @default.
• W2791756039 hasAuthorship W2791756039A5073819873 @default.
• W2791756039 hasAuthorship W2791756039A5082025437 @default.
• W2791756039 hasAuthorship W2791756039A5086361192 @default.
• W2791756039 hasBestOaLocation W27917560391 @default.
• W2791756039 hasConcept C112705442 @default.
• W2791756039 hasConcept C121608353 @default.
• W2791756039 hasConcept C126322002 @default.
• W2791756039 hasConcept C143998085 @default.
• W2791756039 hasConcept C170493617 @default.
• W2791756039 hasConcept C197934379 @default.
• W2791756039 hasConcept C2776996007 @default.
• W2791756039 hasConcept C2778375690 @default.
• W2791756039 hasConcept C2779438470 @default.
• W2791756039 hasConcept C2780580887 @default.
• W2791756039 hasConcept C71924100 @default.
• W2791756039 hasConcept C72563966 @default.
• W2791756039 hasConcept C98274493 @default.
• W2791756039 hasConceptScore W2791756039C112705442 @default.

• next